Claims for Patent: 9,534,058
✉ Email this page to a colleague
Summary for Patent: 9,534,058
Title: | Anti-CD324 monoclonal antibodies and uses thereof |
Abstract: | Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. |
Inventor(s): | Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) |
Assignee: | ABBVIE STEMCENTRX LLC (North Chicago, IL) |
Application Number: | 14/377,343 |
Patent Claims: | 1. An isolated anti-CD324 antibody or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof is selected from the group
consisting of: a) an antibody comprising a light chain variable region set forth as SEQ ID NO: 20, and comprising a heavy chain variable region set forth as SEQ ID NO: 21; b) an antibody comprising a light chain variable region set forth as SEQ ID NO:
22, and comprising a heavy chain variable region set forth as SEQ ID NO: 23; c) an antibody comprising a light chain variable region set forth as SEQ ID NO: 24, and comprising a heavy chain variable region set forth as SEQ ID NO: 25; d) an antibody
comprising a light chain variable region set forth as SEQ ID NO: 26, and comprising a heavy chain variable region set forth as SEQ ID NO: 27; e) an antibody comprising a light chain variable region set forth as SEQ ID NO: 28, and comprising a heavy
chain variable region set forth as SEQ ID NO: 29; f) an antibody comprising a light chain variable region set forth as SEQ ID NO: 30, and comprising a heavy chain variable region set forth as SEQ ID NO: 31; g) an antibody comprising a light chain
variable region set forth as SEQ ID NO: 32, and comprising a heavy chain variable region set forth as SEQ ID NO: 33; h) an antibody comprising a light chain variable region set forth as SEQ ID NO: 34, and comprising a heavy chain variable region set
forth as SEQ ID NO: 35; i) an antibody comprising a light chain variable region set forth as SEQ ID NO: 36, and comprising a heavy chain variable region set forth as SEQ ID NO: 37; j) an antibody comprising a light chain variable region set forth as
SEQ ID NO: 38, and comprising a heavy chain variable region set forth as SEQ ID NO: 39; k) an antibody comprising a light chain variable region set forth as SEQ ID NO: 40, and comprising a heavy chain variable region set forth as SEQ ID NO: 41; l) an
antibody comprising a light chain variable region set forth as SEQ ID NO: 42, and comprising a heavy chain variable region set forth as SEQ ID NO: 43; m) an antibody comprising a light chain variable region set forth as SEQ ID NO: 44, and comprising a
heavy chain variable region set forth as SEQ ID NO: 45; n) an antibody comprising a light chain variable region set forth as SEQ ID NO: 46, and comprising a heavy chain variable region set forth as SEQ ID NO: 47; o) an antibody comprising a light chain
variable region set forth as SEQ ID NO: 48, and comprising a heavy chain variable region set forth as SEQ ID NO: 49; p) an antibody comprising a light chain variable region set forth as SEQ ID NO: 50, and comprising a heavy chain variable region set
forth as SEQ ID NO: 51; q) an antibody comprising a light chain variable region set forth as SEQ ID NO: 52, and comprising a heavy chain variable region set forth as SEQ ID NO: 53; r) an antibody comprising a light chain variable region set forth as
SEQ ID NO: 54, and comprising a heavy chain variable region set forth as SEQ ID NO: 55; s) an antibody comprising a light chain variable region set forth as SEQ ID NO: 56, and comprising a heavy chain variable region set forth as SEQ ID NO: 57; t) an
antibody comprising a light chain variable region set forth as SEQ ID NO: 58, and comprising a heavy chain variable region set forth as SEQ ID NO: 59; u) an antibody comprising a light chain variable region set forth as SEQ ID NO: 60, and comprising a
heavy chain variable region set forth as SEQ ID NO: 61; v) an antibody comprising a light chain variable region set forth as SEQ ID NO: 62, and comprising a heavy chain variable region set forth as SEQ ID NO: 63; w) an antibody comprising a light chain
variable region set forth as SEQ ID NO: 64, and comprising a heavy chain variable region set forth as SEQ ID NO: 65; x) an antibody comprising a light chain variable region set forth as SEQ ID NO: 66, and comprising a heavy chain variable region set
forth as SEQ ID NO: 67; y) an antibody comprising a light chain variable region set forth as SEQ ID NO: 68, and comprising a heavy chain variable region set forth as SEQ ID NO: 69; and z) an antibody comprising a light chain variable region set forth
as SEQ ID NO: 70, and comprising a heavy chain variable region set forth as SEQ ID NO: 71.
2. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 20 for CDR-L1, residues 50-56 of SEQ ID NO: 20 for CDR-L2, and residues 89-97 of SEQ ID NO: 20 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 21 for CDR-H1, residues 50-65 of SEQ ID NO: 21 for CDR-H2 and residues 95-102 of SEQ ID NO: 21 for CDR-H3, wherein the residues are numbered according to Kabat; b) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 22 for CDR-L1, residues 50-56 of SEQ ID NO: 22 for CDR-L2, and residues 89-97 of SEQ ID NO: 22 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2 and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat; c) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 24 for CDR-L1, residues 50-56 of SEQ ID NO: 24 for CDR-L2, and residues 89-97 of SEQ ID NO: 24 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 25 for CDR-H1, residues 50-65 of SEQ ID NO: 25 or SEQ ID NO. 73 for CDR-H2 and residues 95-102 of SEQ ID NO: 25 for CDR-H3, wherein the residues are numbered according to Kabat; d) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 26 for CDR-L1, residues 50-56 of SEQ ID NO: 26 for CDR-L2, and residues 89-97 of SEQ ID NO: 26 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2 and residues 95-102 of SEQ ID NO: 27 for CDR-H3, wherein the residues are numbered according to Kabat; e) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 28 for CDR-L1, residues 50-56 of SEQ ID NO: 28 for CDR-L2, and residues 89-97 of SEQ ID NO: 28 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 29 for CDR-H1, residues 50-65 of SEQ ID NO: 29 for CDR-H2 and residues 95-102 of SEQ ID NO: 29 for CDR-H3, wherein the residues are numbered according to Kabat; f) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 30 for CDR-L1, residues 50-56 of SEQ ID NO: 30 for CDR-L2, and residues 89-97 of SEQ ID NO: 30 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 31 for CDR-H1, residues 50-56 of SEQ ID NO: 31 for CDR-H2 and residues 95-102 of SEQ ID NO: 31 for CDR-H3, wherein the residues are numbered according to Kabat; g) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 32 for CDR-L1, residues 50-56 of SEQ ID NO: 32 for CDR-L2, and residues 89-97 of SEQ ID NO: 32 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 33 for CDR-H1, residues 50-56of SEQ ID NO: 33 for CDR-H2 and residues 95-102 of SEQ ID NO: 33 for CDR-H3, wherein the residues are numbered according to Kabat; h) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 34 for CDR-L1, residues 50-56 of SEQ ID NO: 34 for CDR-L2, and residues 89-97 of SEQ ID NO: 34 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 35 for CDR-H1, residues 50-65 of SEQ ID NO: 35 for CDR-H2 and residues 95-102 of SEQ ID NO: 35 for CDR-H3, wherein the residues are numbered according to Kabat; i) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 36 for CDR-L1, residues 50-56 of SEQ ID NO: 36 for CDR-L2, and residues 89-97 of SEQ ID NO: 36 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-34 of SEQ ID NO: 37 for CDR-H1, residues 50-65 of SEQ ID NO: 37 for CDR-H2 and residues 95-102 of SEQ ID NO: 37 for CDR-H3, wherein the residues are numbered according to Kabat; j) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 38 for CDR-L1, residues 50-56 of SEQ ID NO: 38 for CDR-L2, and residues 89-97 of SEQ ID NO: 38 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 39 for CDR-H1, residues 50-65 of SEQ ID NO: 39 for CDR-H2 and residues 95-102 of SEQ ID NO: 39 for CDR-H3, wherein the residues are numbered according to Kabat; k) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 40 for CDR-L1, residues 50-56 of SEQ ID NO: 40 for CDR-L2, and residues 89-97 of SEQ ID NO: 40 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 41 for CDR-H1, residues 50-65 of SEQ ID NO: 41 for CDR-H2 and residues 95-102 of SEQ ID NO: 41 for CDR-H3, wherein the residues are numbered according to Kabat; l) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 42 for CDR-L1, residues 50-56 of SEQ ID NO: 42 for CDR-L2, and residues 89-97 of SEQ ID NO: 42 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2 and residues 95-102 of SEQ ID NO: 43 for CDR-H3, wherein the residues are numbered according to Kabat; m) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 44 for CDR-L1, residues 50-56 of SEQ ID NO: 44 for CDR-L2, and residues 89-97 of SEQ ID NO: 44 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 45 for CDR-H1, residues 50-65 of SEQ ID NO: 45 for CDR-H2 and residues 95-102 of SEQ ID NO: 45 for CDR-H3, wherein the residues are numbered according to Kabat; n) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 46 for CDR-L1, residues 50-56 of SEQ ID NO: 46 for CDR-L2, and residues 89-97 of SEQ ID NO: 46 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 47 for CDR-H1, residues 50-65 of SEQ ID NO: 47 for CDR-H2 and residues 95-102 of SEQ ID NO: 47 for CDR-H3, wherein the residues are numbered according to Kabat; o) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 48 for CDR-L1, residues 50-56 of SEQ ID NO: 48 for CDR-L2, and residues 89-97 of SEQ ID NO: 48 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 49 for CDR-H1, residues 50-65 of SEQ ID NO: 49 for CDR-H2 and residues 95-102 of SEQ ID NO: 49 for CDR-H3, wherein the residues are numbered according to Kabat; p) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 50 for CDR-L1, residues 50-56 of SEQ ID NO: 50 for CDR-L2, and residues 89-97 of SEQ ID NO: 50 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 51 for CDR-H1, residues 50-65 of SEQ ID NO: 51 for CDR-H2 and residues 95-102 of SEQ ID NO: 51 for CDR-H3, wherein the residues are numbered according to Kabat; q) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 52 for CDR-L1, residues 50-56 of SEQ ID NO: 52 for CDR-L2, and residues 89-97 of SEQ ID NO: 52 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 53 for CDR-H1, residues 50-65 of SEQ ID NO: 53 for CDR-H2 and residues 95-102 of SEQ ID NO: 53 for CDR-H3, wherein the residues are numbered according to Kabat; r) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 54 for CDR-L1, residues 50-56 of SEQ ID NO: 54 for CDR-L2, and residues 89-97 of SEQ ID NO: 54 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 55 for CDR-H1, residues 50-65 of SEQ ID NO: 55 for CDR-H2 and residues 95-102 of SEQ ID NO: 55 for CDR-H3, wherein the residues are numbered according to Kabat; s) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 56 for CDR-L1, residues 50-56 of SEQ ID NO: 56 for CDR-L2, and residues 89-97 of SEQ ID NO: 56 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 57 for CDR-H1, residues 50-65 of SEQ ID NO: 57 for CDR-H2 and residues 95-102 of SEQ ID NO: 57 for CDR-H3, wherein the residues are numbered according to Kabat; t) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 58 for CDR-L1, residues 50-56 of SEQ ID NO: 58 for CDR-L2, and residues 89-97 of SEQ ID NO: 58 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 59 for CDR-H1, residues 50-65 of SEQ ID NO: 59 for CDR-H2 and residues 95-102 of SEQ ID NO: 59 for CDR-H3, wherein the residues are numbered according to Kabat; u) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 60 for CDR-L1, residues 50-56 of SEQ ID NO: 60 for CDR-L2, and residues 89-97 of SEQ ID NO: 60 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 61 for CDR-H1, residues 50-65 of SEQ ID NO: 61 for CDR-H2 and residues 95-102 of SEQ ID NO: 61 for CDR-H3, wherein the residues are numbered according to Kabat; v) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 62 for CDR-L1, residues 50-56 of SEQ ID NO: 62 for CDR-L2, and residues 89-97 of SEQ ID NO: 62 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 63 for CDR-H1, residues 50-65 of SEQ ID NO: 63 for CDR-H2 and residues 95-102 of SEQ ID NO: 63 for CDR-H3, wherein the residues are numbered according to Kabat; w) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 64 for CDR-L1, residues 50-56 of SEQ ID NO: 64 for CDR-L2, and residues 89-97 of SEQ ID NO: 64 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 65 for CDR-H1, residues 50-65 of SEQ ID NO: 65 for CDR-H2 and residues 95-102 of SEQ ID NO: 65 for CDR-H3, wherein the residues are numbered according to Kabat; x) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 66 for CDR-L1, residues 50-56 of SEQ ID NO: 66 for CDR-L2, and residues 89-97 of SEQ ID NO: 66 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 67 for CDR-H1, residues 50-65 of SEQ ID NO: 67 for CDR-H2 and residues 95-102 of SEQ ID NO: 67 for CDR-H3, wherein the residues are numbered according to Kabat; y) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 68 for CDR-L1, residues 50-56 of SEQ ID NO: 68 for CDR-L2, and residues 89-97 of SEQ ID NO: 68 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 69 for CDR-H1, residues 50-65 of SEQ ID NO: 69 for CDR-H2 and residues 95-102 of SEQ ID NO: 69 for CDR-H3, wherein the residues are numbered according to Kabat; and z) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 70 for CDR-L1, residues 50-56 of SEQ ID NO: 70 for CDR-L2, and residues 89-97 of SEQ ID NO: 70 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 71 for CDR-H1, residues 50-65 of SEQ ID NO: 71 for CDR-H2 and residues 95-102 of SEQ ID NO: 71 for CDR-H3, wherein the residues are numbered according to Kabat. 3. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 2, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a) an antibody comprising a light chain variable region set forth as SEQ ID NO: 20, and comprising a heavy chain variable region set forth as SEQ ID NO: 21; b) an antibody comprising a light chain variable region set forth as SEQ ID NO: 22, and comprising a heavy chain variable region set forth as SEQ ID NO: 23; c) an antibody comprising a light chain variable region set forth as SEQ ID NO: 24, and comprising a heavy chain variable region set forth as SEQ ID NO: 25; d) an antibody comprising a light chain variable region set forth as SEQ ID NO: 26, and comprising a heavy chain variable region set forth as SEQ ID NO: 27; e) an antibody comprising a light chain variable region set forth as SEQ ID NO: 28, and comprising a heavy chain variable region set forth as SEQ ID NO: 29; f) an antibody comprising a light chain variable region set forth as SEQ ID NO: 30, and comprising a heavy chain variable region set forth as SEQ ID NO: 31; g) an antibody comprising a light chain variable region set forth as SEQ ID NO: 32, and comprising a heavy chain variable region set forth as SEQ ID NO: 33; h) an antibody comprising a light chain variable region set forth as SEQ ID NO: 34, and comprising a heavy chain variable region set forth as SEQ ID NO: 35; i) an antibody comprising a light chain variable region set forth as SEQ ID NO: 36, and comprising a heavy chain variable region set forth as SEQ ID NO: 37; j) an antibody comprising a light chain variable region set forth as SEQ ID NO: 38, and comprising a heavy chain variable region set forth as SEQ ID NO: 39; k) an antibody comprising a light chain variable region set forth as SEQ ID NO: 40, and comprising a heavy chain variable region set forth as SEQ ID NO: 41; l) an antibody comprising a light chain variable region set forth as SEQ ID NO: 42, and comprising a heavy chain variable region set forth as SEQ ID NO: 43; m) an antibody comprising a light chain variable region set forth as SEQ ID NO: 44, and comprising a heavy chain variable region set forth as SEQ ID NO: 45; n) an antibody comprising a light chain variable region set forth as SEQ ID NO: 46, and comprising a heavy chain variable region set forth as SEQ ID NO: 47; o) an antibody comprising a light chain variable region set forth as SEQ ID NO: 48, and comprising a heavy chain variable region set forth as SEQ ID NO: 49; p) an antibody comprising a light chain variable region set forth as SEQ ID NO: 50, and comprising a heavy chain variable region set forth as SEQ ID NO: 51; q) an antibody comprising a light chain variable region set forth as SEQ ID NO: 52, and comprising a heavy chain variable region set forth as SEQ ID NO: 53; r) an antibody comprising a light chain variable region set forth as SEQ ID NO: 54, and comprising a heavy chain variable region set forth as SEQ ID NO: 55; s) an antibody comprising a light chain variable region set forth as SEQ ID NO: 56, and comprising a heavy chain variable region set forth as SEQ ID NO: 57; t) an antibody comprising a light chain variable region set forth as SEQ ID NO: 58, and comprising a heavy chain variable region set forth as SEQ ID NO: 59; u) an antibody comprising a light chain variable region set forth as SEQ ID NO: 60, and comprising a heavy chain variable region set forth as SEQ ID NO: 61; v) an antibody comprising a light chain variable region set forth as SEQ ID NO: 62, and comprising a heavy chain variable region set forth as SEQ ID NO: 63; w) an antibody comprising a light chain variable region set forth as SEQ ID NO: 64, and comprising a heavy chain variable region set forth as SEQ ID NO: 65; x) an antibody comprising a light chain variable region set forth as SEQ ID NO: 66, and comprising a heavy chain variable region set forth as SEQ ID NO: 67; y) an antibody comprising a light chain variable region set forth as SEQ ID NO: 68, and comprising a heavy chain variable region set forth as SEQ ID NO: 69; and z) an antibody comprising a light chain variable region set forth as SEQ ID NO: 70, and comprising a heavy chain variable region set forth as SEQ ID NO: 71. 4. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is selected from the group consisting of monoclonal antibodies, chimeric antibodies, and humanized antibodies. 5. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 2, comprising a light chain variable region set forth as SEQ ID NO: 72, and comprising a light chain variable region set forth as SEQ ID NO: 73. 6. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent. 7. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 5, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent. 8. A bispecific antibody comprising the antibody of claim 1 and an antibody that recognizes an epitope present on an antigen selected from the group consisting of OCT4, Nanog, STAT3, EPCAM, CD24, CD34, NB84, TrkA, GD2, CD133, CD20, CD56, CD29, B7H3, CD46, transferrin receptor, JAM3, carboxypeptidase M, oncostatin M, Lgr5, Lgr6, CD325, nectin-4, nestin, Soxl, Bmi-1, eed, easyhl, easyh2, mf2, yyl, smarcA3, smarckA5, smarcD3, smarcE1, m1lt3, DLL1, DLL4, FZD1, FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9, FZD10, WNT2, WNT2B, WNT3, WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC, (TCF4) SLC7A8, SLC44A4, IL1RAP, TEM8, TMPRSS4, MUC16, GPRC5B, SLC6A14, SLC4A11, PPAP2C, CAV1, CAV2, PTPN3, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA9, EPHB1, EPHB2, EPHB3, EPHB4, EPH5, EPHB6, EFNA1, EFNA2, EFNA3, EFNA5, EFNA6, EFNB1, EFNB2, EFNB3, SLC1A1, CX3CL1, ADORA2A, MPZL1, F1110052, C4.4A, EDG3, RARRES1, TMEPAI, PTS, CEACAM5, CEACAM6, NID2, STEAP, ABCA3, CRIM1, IL1R1, OPN3, DAF, MUC1, CPD, NMA, ADAMS, GJA1, SLC19A2, ABCA1, PCDH7, ADCY9, SLC39A1, NPC1, ENPP1, N33, GPNMB, LY6E, CELSR1, LRP3, C20orf52, TMEPAI, FLVCR, PCDHA10, GPR54, TGFBR3, SEMA4B, PCDHB2, ABCG2, CD166, AFP, BMP-4, .beta.-catenin, CD2, CD3, CD9, CD14, CD31, CD38, CD44, CD45, CD74, CD90, CXCR4, decorin, APCDD1, PTK7, EGFR, CD105, CD64, CD16, CD16a, CD16b, GLI1, GLI2, CD49b, CD49e and CD49f. 9. The bispecific antibody of claim 8, comprising the antibody of claim 1 and an antibody selected from the group consisting of abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49 and 3F8. 10. A vector comprising a polynucleotide, wherein the polynucleotide encodes a polypeptide comprising a light chain variable region or a heavy chain variable region of an antibody according to claim 3. |
Details for Patent 9,534,058
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-02-08 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2032-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-02-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.